These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26653034)

  • 1. IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.
    Lazzeri S; Orlandi P; Piaggi P; Sartini MS; Casini G; Guidi G; Figus M; Fioravanti A; Di Desidero T; Ripandelli G; Parravano M; Varano M; Nardi M; Bocci G
    Pharmacogenomics; 2016; 17(1):35-9. PubMed ID: 26653034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.
    Lazzeri S; Figus M; Orlandi P; Fioravanti A; Di Desidero T; Agosta E; Sartini MS; Posarelli C; Nardi M; Danesi R; Bocci G
    Pharmacogenomics; 2013 Apr; 14(6):623-30. PubMed ID: 23570466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
    Cruz-Gonzalez F; Cabrillo-Estévez L; López-Valverde G; Cieza-Borrella C; Hernández-Galilea E; González-Sarmiento R
    Graefes Arch Clin Exp Ophthalmol; 2014 Mar; 252(3):469-75. PubMed ID: 24522370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
    Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
    Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.
    Veloso CE; de Almeida LN; Recchia FM; Pelayes D; Nehemy MB
    Ophthalmic Res; 2014; 51(1):1-8. PubMed ID: 24157918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting.
    Boulanger-Scemama E; Querques G; About F; Puche N; Srour M; Mane V; Massamba N; Canoui-Poitrine F; Souied EH
    J Fr Ophtalmol; 2015 Sep; 38(7):620-7. PubMed ID: 25913443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab.
    Airody A; Venugopal D; Allgar V; Gale RP
    Acta Ophthalmol; 2015 Sep; 93(6):e511-2. PubMed ID: 25488611
    [No Abstract]   [Full Text] [Related]  

  • 16. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
    Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
    Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2.
    Kupitz EH; Heeren TF; Holz FG; Charbel Issa P
    Retina; 2015 Dec; 35(12):2619-26. PubMed ID: 26340529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY; Kwon KY; Byeon SH
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
    Subramanian ML; Abedi G; Ness S; Ahmed E; Fenberg M; Daly MK; Houranieh A; Feinberg EB
    Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.